Compare Stocks: BTAI, PCSC, COYA, and BDTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDTX Black Diamond Therapeutics	$1.71 +0.9%	$1.88	$1.60 ▼ $4.94	$97.13M	3.25	1.16 million shs	259,897 shs
BTAI BioXcel Therapeutics	$0.85 +5.2%	$1.09	$0.74 ▼ $8.08	$26.40M	0.27	1.13 million shs	525,865 shs
COYA Coya Therapeutics	$4.44 +5.8%	$4.89	$3.71 ▼ $7.75	$103.93M	0.61	195,581 shs	93,263 shs
PCSC Perceptive Capital Solutions	$11.95	$11.33	$9.95 ▼ $14.47	$97.48M	0.36	238,297 shs	N/A

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDTX Black Diamond Therapeutics	0.00%	-3.98%	-15.92%	-35.00%	-34.75%
BTAI BioXcel Therapeutics	0.00%	-4.66%	-41.45%	-32.67%	-41.02%
COYA Coya Therapeutics	0.00%	-1.41%	-28.50%	+0.48%	-31.20%
PCSC Perceptive Capital Solutions	0.00%	0.00%	+8.64%	+6.98%	+16.02%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDTX Black Diamond Therapeutics	$1.71 +0.9%	$1.88	$1.60 ▼ $4.94	$97.13M	3.25	1.16 million shs	259,897 shs
BTAI BioXcel Therapeutics	$0.85 +5.2%	$1.09	$0.74 ▼ $8.08	$26.40M	0.27	1.13 million shs	525,865 shs
COYA Coya Therapeutics	$4.44 +5.8%	$4.89	$3.71 ▼ $7.75	$103.93M	0.61	195,581 shs	93,263 shs
PCSC Perceptive Capital Solutions	$11.95	$11.33	$9.95 ▼ $14.47	$97.48M	0.36	238,297 shs	N/A

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDTX Black Diamond Therapeutics	0.00%	-3.98%	-15.92%	-35.00%	-34.75%
BTAI BioXcel Therapeutics	0.00%	-4.66%	-41.45%	-32.67%	-41.02%
COYA Coya Therapeutics	0.00%	-1.41%	-28.50%	+0.48%	-31.20%
PCSC Perceptive Capital Solutions	0.00%	0.00%	+8.64%	+6.98%	+16.02%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDTX Black Diamond Therapeutics	2.73	Moderate Buy	$9.83	476.74% Upside
BTAI BioXcel Therapeutics	2.25	Hold	$11.00	1,194.12% Upside
COYA Coya Therapeutics	2.71	Moderate Buy	$15.33	245.73% Upside
PCSC Perceptive Capital Solutions	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest BTAI, PCSC, COYA, and BDTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/20/2026	PCSC Perceptive Capital Solutions	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
7/17/2026	BTAI BioXcel Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	COYA Coya Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	BDTX Black Diamond Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
6/24/2026	PCSC Perceptive Capital Solutions	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
6/12/2026	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$14.00
6/5/2026	COYA Coya Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
5/22/2026	BDTX Black Diamond Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
5/22/2026	BDTX Black Diamond Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/22/2026	BDTX Black Diamond Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/18/2026	BDTX Black Diamond Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDTX Black Diamond Therapeutics	N/A	N/A	$0.53 per share	3.21	$1.97 per share	N/A
BTAI BioXcel Therapeutics	$680K	38.60	N/A	N/A	($4.37) per share	-0.19
COYA Coya Therapeutics	$7.95M	13.09	N/A	N/A	$2.06 per share	2.15
PCSC Perceptive Capital Solutions	N/A	N/A	$0.09 per share	127.23	($0.77) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDTX Black Diamond Therapeutics	$22.37M	-$0.77	N/A	N/A	N/A	N/A	-30.18%	-23.91%	8/6/2026 (Estimated)
BTAI BioXcel Therapeutics	-$69.90M	-$5.75	N/A	N/A	N/A	-11,078.53%	N/A	-201.53%	8/11/2026 (Estimated)
COYA Coya Therapeutics	-$21.23M	-$1.15	N/A	N/A	N/A	-266.10%	-55.86%	-48.86%	8/11/2026 (Estimated)
PCSC Perceptive Capital Solutions	$840K	-$0.06	N/A	N/A	N/A	N/A	-2.70%	-0.84%	N/A

Latest BTAI, PCSC, COYA, and BDTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	BTAI BioXcel Therapeutics	-$0.44	N/A	N/A	N/A	$0.49 million	N/A
8/11/2026	Q2 2026	COYA Coya Therapeutics	-$0.36	N/A	N/A	N/A	$0.13 million	N/A
8/6/2026	Q2 2026	BDTX Black Diamond Therapeutics	-$0.18	N/A	N/A	N/A	N/A	N/A
7/15/2026	Q2 2026	PCSC Perceptive Capital Solutions	N/A	-$0.01	N/A	-$0.01	N/A	N/A
5/15/2026	Q1 2026	BTAI BioXcel Therapeutics	-$0.5325	-$0.54	-$0.0075	-$0.54	$0.38 million	$0.21 million
5/12/2026	Q1 2026	COYA Coya Therapeutics	-$0.39	-$0.32	+$0.07	-$0.32	$0.15 million	$0.25 million
5/7/2026	Q1 2026	BDTX Black Diamond Therapeutics	-$0.18	-$0.16	+$0.02	-$0.16	$25.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	N/A
BTAI BioXcel Therapeutics	N/A	N/A	N/A	N/A	N/A
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
PCSC Perceptive Capital Solutions	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDTX Black Diamond Therapeutics	N/A	8.46	8.46
BTAI BioXcel Therapeutics	N/A	0.62	0.61
COYA Coya Therapeutics	N/A	15.02	15.02
PCSC Perceptive Capital Solutions	N/A	0.20	0.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDTX Black Diamond Therapeutics	95.47%
BTAI BioXcel Therapeutics	30.68%
COYA Coya Therapeutics	39.75%
PCSC Perceptive Capital Solutions	N/A

Insider Ownership

Company	Insider Ownership
BDTX Black Diamond Therapeutics	9.29%
BTAI BioXcel Therapeutics	3.70%
COYA Coya Therapeutics	6.10%
PCSC Perceptive Capital Solutions	22.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDTX Black Diamond Therapeutics	90	57.30 million	51.98 million	Optionable
BTAI BioXcel Therapeutics	90	30.88 million	29.74 million	No Data
COYA Coya Therapeutics	6	23.46 million	22.03 million	Not Optionable
PCSC Perceptive Capital Solutions	N/A	8.16 million	6.36 million	N/A

BTAI, PCSC, COYA, and BDTX Headlines

Recent News About These Companies

126,083 Shares in Perceptive Capital Solutions Corp. $PCSC Bought by DLD Asset Management LP

July 23, 2026 | marketbeat.com

Perceptive Capital Solutions Corp. $PCSC Shares Sold by Crcm LP

July 23, 2026 | marketbeat.com

Perceptive Capital Solutions Corp Announces Change of Date of Extraordinary General Meeting of Shareholders

July 9, 2026 | prnewswire.com

Perceptive Capital Solutions Corp and Freenome Announce Effectiveness of Registration Statement for Proposed Business Combination

June 18, 2026 | prnewswire.com

Perceptive Capital Shareholders Approve Extension for Freenome Merger

June 10, 2026 | tipranks.com

Perceptive Capital Solutions Corp. Cl A PCSC (U.S.: Nasdaq)

August 1, 2025 | wsj.com

Perceptive Capital Solutions Corp (PCSC) - Yahoo Finance

June 30, 2025 | sg.finance.yahoo.com

Perceptive Capital Solutions Corp. Cl A

March 23, 2025 | wsj.com

PCSC Perceptive Capital Solutions Corp

August 28, 2024 | seekingalpha.com

Perceptive Capital Solutions Corp (PCSC)

August 7, 2024 | uk.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTAI, PCSC, COYA, and BDTX Company Descriptions

Black Diamond Therapeutics NASDAQ:BDTX

$1.70 +0.02 (+0.89%)

As of 03:11 PM Eastern

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

BioXcel Therapeutics NASDAQ:BTAI

$0.85 +0.04 (+5.20%)

As of 03:10 PM Eastern

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Coya Therapeutics NASDAQ:COYA

$4.43 +0.25 (+5.85%)

As of 03:08 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Perceptive Capital Solutions NASDAQ:PCSC

$11.95 0.00 (0.00%)

As of 07/21/2026

Perceptive Capital Solutions Corp is a blank check company. It formed for the purpose of entering into a combination with one or more businesses or entities. Perceptive Capital Solutions Corp is based in NEW YORK.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BTAI, PCSC, COYA, and BDTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BTAI, PCSC, COYA, and BDTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BTAI, PCSC, COYA, and BDTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTAI, PCSC, COYA, and BDTX Company Descriptions

Black Diamond Therapeutics NASDAQ:BDTX

BioXcel Therapeutics NASDAQ:BTAI

Coya Therapeutics NASDAQ:COYA

Perceptive Capital Solutions NASDAQ:PCSC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BTAI, PCSC, COYA, and BDTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BTAI, PCSC, COYA, and BDTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BTAI, PCSC, COYA, and BDTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTAI, PCSC, COYA, and BDTX Company Descriptions

Black Diamond Therapeutics NASDAQ:BDTX

BioXcel Therapeutics NASDAQ:BTAI

Coya Therapeutics NASDAQ:COYA

Perceptive Capital Solutions NASDAQ:PCSC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools